Pharma Pulse 10/11/24: Critical Conversations Between Supply Chain Teams, Mental Health May Play a Role in Vitiligo Treatment Efficacy & more
The latest news for pharma industry insiders.
LogiPharma USA 2024: Critical Conversations Between Supply Chain Teams During API Sourcing
Lucy Alexander, capabilities lead, global supply chain and strategy, AstraZeneca, discusses critical conversations that supply chain teams and partners must partake in during API sourcing at LogiPharma USA 2024.
Mental Health May Play a Role in Vitiligo Treatment Efficacy, Study Shows
Mental health and vitiligo treattment outcomes may be associated because of a brain-skin axis, a pathway that links emotional stress to skin conditions.
Nobel Prize in Chemistry Awarded to Trio Who Cracked the Code of Proteins
Google DeepMind’s John Jumper and Demis Hassabis share honor with David Baker for transforming ability to understand human biology.
New Study: Patients Unlikely to See Out-Of-Pocket Drug Savings from the Inflation Reduction Act
New research contradicts promises of savings at the pharmacy counter for Medicare beneficiaries from the Inflation Reduction Act’s (IRA) drug pricing provisions. In fact, the study suggests some patients may pay more. In a research brief commissioned by We Work For Health with analysis performed by the IQVIA Institute for Human Data Science, researchers estimated what patients will actually pay for the 10 Part D medicines chosen by the Centers for Medicare and Medicaid Services for government price controls. The IQVIA Institute calculated how changes in Medicare coverage and other factors will impact patient out-of-pocket costs. The study reveals how unintended consequences of the law could lead to negative impacts for seniors, including increased costs and coverage barriers for certain medications.
High payer rejection rates faced by new drugs in the US market are a major challenge for biopharma companies. According to recent data reported by Pharmaceutical Executive, 69% are rejected within the first year of launch. To address this issue, it's essential to re-evaluate your payer launch strategies. Partnering with experts in this field can ensure that you are implementing best-in-class launch strategies that can improve patient access and maximize the commercial potential of your products. Read the full article here: https://lnkd.in/eJ5E24it
We can help you overcome the challenges of the competitive payer landscape. Let's connect to discuss your specific needs at:
https://lnkd.in/eadTaaSM
#PharmaceuticalMarketAccess #PayerRelations #DrugLaunchStrategies
Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.
